Kornimate/medical-research-clean huggingface dataset:
the effect of continuous accompanying support in the active phase on labor pain, duration and satisfaction

Conditions: Continuous Birth Support

Summary: this study was planned to determine the effect of continuous accompanying support during the active phase on labor pain, duration and satisfaction.

participants who comes into childbirth needs the support of people around her in order to cope with the stress, anxiety and labor pain she experiences. this support is the continuous birth support given from the time the participants comes to the hospital until the birth of the baby. having someone who supports the woman during the birth process will provide a positive birth experience for pregnant women. at the same time, the feeling of pain of the supported woman will be reduced and the delivery time will be shortened. this randomized controlled study was planned to be performed on primiparous pregnant women between january 2023 and january 2024. the data of the study will be collected with "personal information form", "visual analog scale". the study was divided into two groups as experimental and control groups. 55 participants in the experiment -55 participants will be randomized to the control group. participants meeting the inclusion criteria will be asked to rate their pain and satisfaction from 0 to 10 with the vas 4 cm, 6 cm, 8 cm and fully open. while both groups receive routine midwife support, when the experimental group reaches 4 cm, a person they want will be taken with them and continuous support will be given until there is a dilation of 10 cm.

Eligibility criteria:
inclusion criteria: * 18-35 years old * being literate * fluent and speaking turkish * primiparous * spontaneous vaginal delivery planned * at the beginning of the active phase (dilatation 4 cm) * pregnant women who agreed to participate in the research exclusion criteria: * presence of a health problem in the mother during pregnancy * at risk of fetal anomaly * having multiple pregnancy * administering analgesic medication during labor

Keywords: continuous birth support birth time labor pain satisfaction
pediatric hypertension registry (phreg)

Conditions: Hypertension; Pediatric Disorder

Summary: pediatric hypertension is increasingly common and is a precursor for adult cardiovascular and renal disease. but even during childhood, hypertension is associated with significant morbidity, including cognitive impairment and organ damage. however, the cause of pediatric hypertension, the response to treatment, and the mechanisms behind organ damage are incompletely understood. due to these limitations, there are no first-line medications, and treatment is often inadequate. an improved comprehension of the course of pediatric hypertension could enhance clinical care. the goal of this proposal is to create a registry of patients with hypertension to better enable research into this important disease. this patient registry will enhance the investigators ability to quickly collect and analyze data for research studies.

the investigators will include all subjects evaluated at the brenner children's hospital pediatric nephrology clinic since january 1st, 2013 with a diagnosis of high blood pressure confirmed with three separate blood pressure measurements \>=90th percentile for age, sex, and height, or \>120/80 mmhg. the investigators will exclude patients whose initial evaluation occurred on or after their 18th birthday.

Eligibility criteria:
inclusion criteria: - patients at one of the following : wake forest baptist health brenner children's hospital pediatric nephrology clinic emory university pediatric nephrology * diagnosis of hypertension confirmed with three separate blood pressure measurements * diagnosis after january 2013 * \>90th percentile for age, sex, height, or \>120/80. exclusion criteria: - patients whose initial evaluation occurred on or after their 18th birthday.

Keywords: hypertension
flu a+b nasal swab clinical study

Conditions: Influenza

Summary: the purpose of this clinical study is to obtain clearance for the nasal swab sample type by demonstrating the performance characteristics of the flu a+b test versus standard laboratory culture for influenza a and b viruses using nasal swab samples.

patients exhibiting symptoms of influenza enrolled in a fashion that confidentiality of all personal health information is maintained. no patient treatment is affected by enrollment in this trial.

Eligibility criteria:
inclusion criteria: * male and female of all age groups * patients exhibiting influenza symptoms (i.e., fever, body aches, headaches, cough, sore throat, and other respiratory symptoms) at the time of examination * patients must either present with a fever (\>100ºf; \>37.8ºc) at time of examination or have had a fever (\>100ºf; \>37.8ºc) or declare at time of the examination that they had a fever within the previous 3 days prior to the examination * must be able to collect sample using the nasal swab sample type exclusion criteria: * patients with no fever at time of examination or within the 3 days prior to examination and/or are currently undergoing treatment (including anti-virals) will be excluded from the study.
continuous monitoring of vital parameters for early detection of clinical deterioration in hospitalized patients

Conditions: Continuous Wireless Vital Parameter Monitoring

Summary: for patients admitted to the medical ward, it is often difficult to predict if their clinical condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to icu admission, or unanticipated cardiac arrest. such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. new continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. the ward project aims to determine the correlation between cardiopulmonary micro events and clinical adverse events during the first four days after hospital admission.


Eligibility criteria:
inclusion criteria: * adults \>18 years * acute hospitalization or discharge from intensive care unit (icu) after an admission of at least 24 hours. * early warning score (ews) ≥4 at least once from admission and until inclusion * one of the following tentative diagnoses as the primary reason for admission: pneumonia, dyspnea, acute myocardial infarction, heartfailure or sepsis * inclusion conversation possible within 12 hours of admission or discharge from icu exclusion criteria: * patients that cannot cooperate * patients that cannot give informed consent * patients with ews≥4 that is not of presumed physical origin * patients with allergies to plaster or silicone * patients with pacemaker or icd * patients with treatment limitations (no resuscitation or no admission to icu) * patients with expected discharge within 24 hours * patients that have been included in the ward-copd study (h-18026653)
personalized comprehensive diabetes support for children with newly diagnosed type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the goal of this clinical trial is to learn if access to a diabetes coach improves quality of life (qol) for families of children with newly diagnosed type 1 diabetes. the main questions it aims to answer are: 1. determine if there are beneficial effects on diabetes-related qol at the end of the 6-month intervention. 2. determine if potential beneficial effects persist beyond completion of the support intervention, as measured by diabetes-related qol at 12 months and 24 months following diagnosis participants assigned to the intervention group will have access to a diabetes coach for 6 months following type 1 diabetes diagnosis. they will be compared to participants who are assigned to the control group and are receiving usual care.


Eligibility criteria:
inclusion criteria: * families of children 16 years of age or younger with a new diagnosis * stable living situation such that the same caregivers are anticipated to be caring for the child during the full 2-year study duration. exclusion criteria: * families of children older than 16 years * children from non-english speaking families
evaluating treatment of anemia in subjects with non-myeloid malignanciesreceiving multicycle chemotherapy

Conditions: Anemia; Non-Myeloid Malignancies; Cancer

Summary: the purpose of this study is to compare the effect of darbepoetin alfa administered in a weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.


Eligibility criteria:
inclusion criteria: - planned chemotherapy treatment - anemia (hemoglobin concentration less than or equal to 11.0 g/dl) - adequate renal and liver function - eastern cooperative oncology group (ecog) 0 to 2 - subjects must provide written informed consent exclusion criteria: - known history of seizure disorder - known primary hematologic disorder causing anemia other than non-myeloid malignancies - unstable/uncontrolled cardiac condition - clinically significant inflammatory disease - known positive test for hiv infection - transfusion within 4 weeks of randomization - neutralizing antibodies to any erythropoietic agent - treatment with erythropoietic therapy within 4 weeks before randomization - received any investigational drug or device within 30 days before randomization - pregnant or breast feeding - not using adequate contraceptive precautions - previously randomized into this study - known hypersensitivity to any products to be administered - concerns for subject's compliance

Keywords: non-myeloid malignancy chemotherapy-induced anemia
fluorouracil plus radiation therapy following surgery in treating patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining chemotherapy with radiation therapy may kill more tumor cells left after surgery. purpose: phase ii trial to study the effectiveness of combining fluorouracil and radiation therapy in treating patients who have undergone surgery for pancreatic cancer.

objectives: * determine the tolerance of adjuvant fluorouracil with concurrent radiotherapy in patients with resected pancreatic adenocarcinoma. * determine survival without local relapse in these patients treated with this regimen. * determine overall survival of these patients treated with this regimen. * determine the effectiveness of this adjuvant therapy in these patients. outline: this is a multicenter study. patients receive high-dose radiotherapy 5 days a week for 5 weeks. patients also receive low-dose radiotherapy 4 times a week during the last 2 weeks of the 5-week course of treatment. patients concurrently receive fluorouracil iv continuously for 5 weeks in the absence of disease progression or unacceptable toxicity. patients are followed for survival. projected accrual: a total of 40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed pancreatic adenocarcinoma * complete macroscopic resection of tumor within past 30 days * no residual visceral or peritoneal metastasis * involvement of vater's ampulla or extrahepatic bile duct allowed * no vesicular or intrahepatic cholangiocarcinomas patient characteristics: age: * 18 to 75 performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * absolute neutrophil count greater than 1,500/mm\^3 * platelet count greater than 100,000/mm\^3 hepatic: * alkaline phosphatase less than 3 times normal * bilirubin less than 1.5 times normal renal: * creatinine less than 1.5 times normal cardiovascular: * no serious cardiac failure pulmonary: * no serious respiratory failure other: * no other untreatable malignant tumors * no serious psychological, familial, social, or geographical conditions that would preclude study prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy for pancreatic adenocarcinoma endocrine therapy: * not specified radiotherapy: * no prior radiotherapy for pancreatic adenocarcinoma * no prior radiotherapy in an anatomically proximal region to treatment area surgery: * see disease characteristics

Keywords: stage i pancreatic cancer stage ii pancreatic cancer stage iii pancreatic cancer adenocarcinoma of the pancreas stage iv pancreatic cancer
relevance evaluation of [68ga]ga-pentixafor for initial staging and detection of minimal residual disease in multiple myeloma patients.

Conditions: Multiple Myeloma

Summary: the aim of our study is to confirm the relevance of pet using \[68ga\]ga-pentixafor ligand, in comparison with fdg, for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years. the prognostic value of positive cxcr4 expression will also be assessed and \[68ga\]ga-pentixafor/fdg discordances explored.


Eligibility criteria:
inclusion criteria: * inclusion criteria are identical to inclusion criteria in midas study (eudract number: 2020-005216-21, clinicaltrials.gov identifier: nct04934475) . exclusion criteria: * non inclusion criteria are identical to non inclusion criteria in midas study (eudract number: 2020-005216-21, clinicaltrials.gov identifier: nct04934475) added with: 1. egfr \< 50 ml/min by mdrd or ckdepi. 2. previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years. 3. patient with uncontrolled insulin-dependent or non-insulin-dependent diabetes mellitus.
trial comparing metabolic effects of telmisartan and amlodipine on hypertensive patients with obesity and diabetes

Conditions: Hypertension; Obesity; Diabetes

Summary: recent studies have shown that obese people are more prone to high blood pressure. with the co-existence of obesity, hypertension and diabetes, patients were more susceptible to hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease. abdominal obesity has often accompanied by substantial accumulation of visceral fat, which increased secretion of many inflammatory mediators, cytokines and adipocytokines and played an important role in cardiovascular and metabolic disease. some reports had shown that angiotensin ii receptor blockers (arb) may improve metabolic profiles in patients with diabetes or metabolic syndrome, in addition to its hypotensive effect. it has been reported that some arb, such as telmisartan and candesartan, can prevent weight gain and high-fat-induced obesity in experimental animals. however, whether telmisartan intervention on improvement of fat deposition and other related metabolic profiles is better than a ccb drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.


Eligibility criteria:
inclusion criteria: * information consent signed * aged 30\~70 years * for whom without anti-hypertensive therapy in 2 weeks：140mmhg≤sbp\<180mmhg，或90mmhg≤dbp\<110mmhg. for whom with anti-hypertensive therapies in 2 weeks：sbp\<180mmhg, 且dbp\<110mmhg * waist circumference higher than 90cm in men, 80cm in women * diagnosed diabetes exclusion criteria: * grade 3 hypertension: sbp≥180mmhg, or dbp≥110mmhg * waist circumference less than 90cm in men, 80cm in women * known allergy or hypersensitivity to trial drugs * nyha grade ⅱ\~ⅳ heart failure, myocardial infarction or cerebrovascular accident in 1 year preceding the trial * acute infections, tumor, severe arrhythmia, mental disease, drug or alcohol abuse * history of hepatitis or cirrhosis * history of severe kidney disease * pregnant, lactation * enrolled in other trials in 3 months * any obstacles of follow-up or compliance

Keywords: hypertension abdominal obesity diabetes treatment
to compare the pharmacokinetics of budesonide delivered by bda mdi to budesonide delivered by pulmicort respules in children with asthma aged 4 to 8 years.

Conditions: Asthma

Summary: to compare the pharmacokinetics of budesonide delivered by bda mdi to budesonide delivered by pulmicort respules in children with asthma aged 4 to 8 years.


Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures. children should provide assent to join the study, as applicable. the child's parent(s) or legally authorized representative (lar) must sign the informed consent form (icf). the lar must be aged ≥18 years old. 2. male or female aged between 4 and 8 years inclusive (not having reached his/her 9th birthday by the time of screening). 3. weigh at least 14 kg or higher. 4. clinician diagnosed asthma of at least 3 months. 5. stable on treatment with albuterol prn and/or ics and/or leukotriene receptor antagonists (ltras) for 2 weeks prior to screening; children taking budesonide in any form at visit 1 will be switched to another corticosteroid with a washout of budesonide of 3 to 7 days. 6. demonstrate ability to correctly use the nebulizer and metered-dose inhaler (mdi) device without a spacer. 7. willingness and ability of the child and parent(s)/lar to comply with the demands of the study as described in the informed consent/assent. exclusion criteria: 1. inability to change from any budesonide therapy to another suitable corticosteroid. 2. history of life-threatening asthma defined as any asthma episode associated with loss of consciousness, intubation or admission to an intensive care unit. 3. unstable asthma as judged by the investigator (eg, any change in asthma therapy within 2 weeks prior to screening or use of more than 2 occasions of rescue medication (albuterol) per day within 1 week prior to screening (potential for rescreen). 4. children receiving regular maintenance treatment with prohibited anti-inflammatory or long-acting bronchodilator asthma medication (inhaled, nebulized, oral, or systemic) within 1 month prior to screening. 5. more than 1 short course of oral/rectal/systemic corticosteroids within 6 months preceding screening (visit 1), or any oral/rectal/systemic corticosteroids within 30 days prior to screening. 6. evidence of active concomitant pulmonary disease other than asthma (children with stable allergic rhinitis will be permitted, as long as, there are no changes in the treatment and the medications do not interfere with the analytical assay methods). 7. upper respiratory infection involving antibiotic treatment not resolved within 14 days prior to visit 1. 8. children with a known or suspected hypersensitivity to albuterol/salbutamol, budesonide or any of the excipients used in the imps.
growth hormone as add-on treatment in severe fibromyalgia with low igf-1 serum levels (56 characters)

Conditions: Fibromyalgia; Growth Hormone Deficiency

Summary: there are evidences of functional growth hormone (gh) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (igf-1), in a subset of fibromyalgia patients. the efficacy of low gh doses versus placebo has been demonstrated in this population. we assessed the efficacy and safety of gh added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low igf-1 levels.


Eligibility criteria:
inclusion criteria: * women greater than 18 years old with severe fibromyalgia and abnormally low igf-1 levels included in a rehabilitation and psychological program and stable under standard intensive treatment for at least 6 months. * all patients fulfilled the 1990 acr diagnostic criteria (1) and had an igf-1 level \<250 ng/ml (or 1 standard deviation bellow the mean value corresponding to age and body surface according to laboratory reference value). * other inclusion criteria were duration of fibromyalgia of 1 year or greater, pain in at least 16 (8 bilateral) of the 18 tender points and a score in the fiq \> 75. * the study was conducted in accordance with the declaration of helsinki and received the local institutional review board and spanish drug agency (nº03-0456) approvals. all patients gave written informed consent prior to their inclusion in the study. exclusion criteria: * disabling physical or mental status * previous or current malignancies, either active or inactive * intracranial space occupying lesion * any relevant endocrine disorder including diabetes mellitus * history of another pituitary disorder * previous treatment with growth hormone * other systemic or joint inflammatory rheumatic conditions; and * known to be hypersensitive to somatropin or any of the excipients. * pregnant women, nursing mothers, or women with childbearing potential not using adequate contraceptive methods were also excluded.

Keywords: fibromyalgia growth hormone igf-1 fiq
epidemiology of idiopathic dilated cardiomyopathy (washington, dc dilated cardiomyopathy study)

Conditions: Cardiovascular Diseases; Heart Diseases; Myocardial Diseases; Asthma; Diabetes Mellitus; Hypertension

Summary: to identify risk factors for idiopathic dilated cardiomyopathy and to examine prognostic factors over a follow-up period of two to three years.

background: idiopathic dilated cardiomyopathy is an often fatal cause of heart failure in young adults which is characterized by dilatation of the ventricles, increased myocardial mass, and impairment of systolic function. dilated cardiomyopathy is more common than hypertrophic and restrictive cardiomyopathy, and the symptoms and physical signs are those of left-sided and eventually right-sided heart failure. histologic findings in the condition include nonspecific interstitial myocardial fibrosis and myocyte hypertrophy. despite the large number of systemic or generalized disease processes which have been associated with secondary dilated cardiomyopathy, the majority of cases are idiopathic. mortality rates from cardiomyopathy have increased dramatically since 1970, and in 1990 over 10,000 deaths annually were attributed to cardiomyopathy in the united states. design narrative: the study had a prospective case-control design. medical records of possible cases of idiopathic dilated cardiomyopathy who were discharged from five washington, d. c. acute care hospitals over a two year period were abstracted so that standard diagnostic criteria could be applied. two neighborhood controls were identified for each case. cases and controls were matched on five year age intervals, sex, and telephone exchange. cases were contacted annually during the two to three year follow-up period to determine vital status. the study determined whether the reported association between idiopathic dilated cardiomyopathy and asthma could be confirmed and the possible role of asthma medications, cigarette smoking, moderate alcohol consumption, and diabetes mellitus in the etiology of idiopathic dilated cardiomyopathy. the role of hypertension was also studied.. statistical analysis consisted of case-control comparisons using conditional logistic regression techniques, and survival analyses using kaplan-meier curves and proportional hazards models. the study was also known as the washington, d.c. dilated cardiomyopathy study. dr. coughlin started his research at georgetown university in washington, d.c. and transferred to tulane university. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria